Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2811 and Durvalumab in Relapsed Small Cell Lung Cancer
NCT04525391Phase 2Terminated
- Start
- Sep 2020
- Primary completion
- Jan 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of defosbarasertib in small cell lung cancer (SCLC). Started Sep 2020; status: terminated.
02
Drugs
defosbarasertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04525391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04525391.